SALT LAKE CITY, Jan. 28, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has published details of its myVision™ Myriad Variant Classification Program in the journal Clinical Genetics. myVision is the most advanced variant classification program available to determine whether a patient's genetic variant (mutation) is benign or deleterious. myVision employs a number of robust scientific methods and is backed by Myriad's 20 years of clinical research and testing in more than one million patients.
Help employers find you! Check out all the jobs and post your resume.
